Clinical TrialsSearch results
Number of results: 1285
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Completed
- A phase 1 study of VLPCOV-01 in COVID-19 vaccinated healthy subjects
- Prevention of infectious disease caused by SARS-CoV-2
- Nobuaki Sato
- 2022-02-01
Other
- A Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of TIN816 in Japanese healthy participants
- Healthy participants
- Maruyama Hideki
- 2023-09-27
Other
- A Phase 1 Study to evaluate tolerability, safety and efficacy of AB122 and AB154 in Combination with Chemotherapy for Patients With Non-Small Cell Lung Cancer
- First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer
- Nasermoaddeli Ali
- 2023-04-11
Completed
- A Phase 1, single-dose and multiple-dose study of DS-2319b inhalation powder to assess the safety and pharmacokinetics of DS-2319a in healthy Japanese subjects
- SARS-CoV-2 Infectious Disease
- Inoguchi Akihiro
- 2021-03-12
Completed
- A phase 1/2 trial of booster dose of VLPCOV-02 vaccine
- Prevention of infectious disease caused by SARS-CoV-2
- Aboshi Masayuki
- 2023-04-10
Completed
- A Phase 2 Trial of ARGX-113 PH20 SC in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- CIDP
- Tsuruyama Eri
- 2021-03-12
Other
- A phase 2 neoadjuvant chemotherapy of Irinotecan (CPT-11) plus Nedaplatin (NDP) for stage 1b2 or 2 cervical cancer of the uterine cervix
- stage 1b2/2 cervical cancer
- Japanese Gynecologic Oncology Group
- 2006-12-21
Other
- A phase 2 open label study to assess the efficacy and safety of beta-glucuronidase enzyme replacement therapy in Japanese patients with mucopolysaccharidosis type VII, Sly disease
- Mucopolysaccharidosis type 7
- Hamazaki Takashi
- 2019-12-23
Recruiting
- A Phase 2 Study of an Anti-MTBR Tau Monoclonal Antibody in Participants with Early Alzheimer's Disease
- Early Alzheimer's disease
- Kahl Anja
- 2024-06-07
Completed
- A phase 2 study of VLPCOV-01 in COVID-19 vaccinated healthy subjects
- Prevention of infectious disease caused by SARS-CoV-2
- Sato Nobuaki
- 2022-09-12